Report: Class-Action Securities Lawsuits Decline But Risks Remain For Life-Sciences Companies

Disgruntled investors lodged fewer securities claims against life-science companies last year. But when they did sue, investors raised familiar issues, often tied to bad news around clinical research and regulatory approvals, according to a law firm report.

The post Report: Class-Action Securities Lawsuits Decline But Risks Remain For Life-Sciences Companies appeared first on Above the Law.

Related Articles

Responses

Your email address will not be published. Required fields are marked *